in far east's article yesterday it gave us an estimate revenue...

in far east's article yesterday it gave us an estimate revenue stream from signing a deal with one of the majors. it paints a pretty picture for ado shareholders if it works out.

but we aren't just working with one major but 7 companies at this stage. 2 ev companies, 2 battery manufactures trinseo wyon and specialised chemical company. 4 with contract proposals. plenty of opportunity there.





and the forgotten side of Anteotech, lifescience, 8 ivd global manufacturers, 1 global vaccine manufacturer (serum institute) and 3 global particle manufacturers. 3 in commercial negotiations.




thats a whole lot of opportunity, if you believe what management are telling us.

then we have several non dilutionary gov't funding that should be close to being granted in the new year.

we will have the production facility up and running in Jan (from yesterdays article). this is so important not just to prove that we can scale up production but to provide enough AnteoX for testing and expansion.

ev1 spent $60k this month, if we use $300/l (again from yesterdays article) that would be 200l of anteoX. add the extra litres for our own testing and the other 6 companies and we definitely need the production facility up and running.

if funding is granted and production capacity is increased, will it increase more opportunities? certainly looks like it with "additional clean energy partnerships" and "development partnerships - anode optimisation" and "development agreements - ev companies"



even if part of the above works out, it will make 2024 a great year for ado holders. GLTAH.........